NeuroScientific Biopharmaceuticals clears key US Crohn’s trial hurdle

The Sydney Morning Herald - Oct 13, 2026

NeuroScientific Biopharmaceuticals has landed key US backing for its Phase 2 stem cell Crohn’s trial, green-lighting a planned year-end start subject to final preparations.

Read full article

More News

Sign Up Now

Subscribe to us for the latest news from Banking Reporter

Banking Reporter

Banking Reporter is the largest-circulated online business news in the United States, bringing a whole new genre of business journalism more up close and more incisive.